TG Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- TG Therapeutics's estimated annual revenue is currently $152k per year.
- TG Therapeutics received $18.1M in venture funding in March 2014.
- TG Therapeutics's estimated revenue per employee is $376
- TG Therapeutics's total funding is $205M.
Employee Data
- TG Therapeutics has 404 Employees.
- TG Therapeutics grew their employee count by 22% last year.
TG Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CFO | Reveal Email/Phone |
2 | Chief Commercial Officer | Reveal Email/Phone |
3 | Controller, VP | Reveal Email/Phone |
4 | VP, Head Global Regulatory Affairs | Reveal Email/Phone |
5 | VP, Information Technology | Reveal Email/Phone |
6 | VP Program Management | Reveal Email/Phone |
7 | VP, Head Medical Affairs | Reveal Email/Phone |
8 | SVP Biologics Operations | Reveal Email/Phone |
9 | VP - Payer, Trade & Distribution | Reveal Email/Phone |
10 | Head Business Development | Reveal Email/Phone |
TG Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $0.6M | 4 | -20% | N/A | N/A |
#2 | $6.7M | 43 | 8% | N/A | N/A |
#3 | $34.4M | 222 | -1% | N/A | N/A |
#4 | $5.2M | 67 | 0% | $10M | N/A |
#5 | $2M | 13 | 0% | N/A | N/A |
#6 | $7.5M | 37 | 0% | $51.6M | N/A |
#7 | $0.3M | 2 | -50% | N/A | N/A |
#8 | $4.3M | 21 | -16% | $3.3M | N/A |
#9 | $3.6M | 23 | 0% | N/A | N/A |
#10 | $4.3M | 56 | -8% | $118M | N/A |
What Is TG Therapeutics?
TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently, the company is developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. TG Therapeutics is also developing TGR-1202, an orally available PI3K delta inhibitor. The delta isoform of PI3K is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of B-lymphocytes. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies. The Company also has pre-clinical programs to develop IRAK4 inhibitors, and anti-PD-L1 and anti-GITR antibodies. TG Therapeutics is headquartered in New York City and is traded on NASDAQ under the ticker symbol "TGTX".
keywords:Biotechnology,Cleantech,Healthcare,Marketing,Pharmaceuticals,Wind Power
$205M
Total Funding
404
Number of Employees
$152k
Revenue (est)
22%
Employee Growth %
N/A
Valuation
N/A
Accelerator
TG Therapeutics News
If you are familiar with the firm, I suggest that you skip to the subsequent section. Operating out of New York, TG Therapeutics is focused on...
Given all my analysis of TG Therapeutics, I am seriously debating doubling down at the lowest price possible for TGTX stock. Read why here.
Read TG Therapeutics, Inc. (NASDAQ:TGTX) Given Consensus Recommendation of Hold by Brokerages at Defense World.
NEW YORK, Nov. 04, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for the third quarter ended September 30, 2021 and recent company developments, along with a business outlook for the remainder of 2021. Michael S. Weiss, the Company's Chairma ...
TG Therapeutics Provides Business Update and Reports Third Quarter 2021 Financial Results Conference call to be held today, Thursday, November 4, 2021 at 8:30 AM ET New York, NY, (November 4, 2021) - TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for the third quart ...
Other Companies in New York
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $66.7M | 404 | 0% | $401M |
#2 | $66.7M | 404 | -15% | $161M |
#3 | $146.5M | 404 | 6% | N/A |
#4 | $80.8M | 404 | 2% | N/A |
#5 | $35M | 405 | 0% | N/A |
TG Therapeutics Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2014-03-13 | $18.1M | Undisclosed | Article |